Who are the leading innovators in miRNA chemical synthesis for the pharmaceutical industry?
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: miRNA chemical synthesis.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
miRNA chemical synthesis is a key innovation area in pharmaceutical
MicroRNAs (miRNAs) are a class of small, non-coding double stranded RNAs (dsRNAs) of 21-25 nucleotides in length, transcribed by the endogenous genome. A variety of chemical modifications are used to facilitate invasion into the miRNA-induced silencing complex. There are three reactions that can be done, which include 2’-O-methyl-group (OMe)-modified oligonucleotides, locked nucleic acid (LNA)-modified oligonucleotides, and 2’-O-methoxyethyl (MOE) modified oligonucleotides.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of miRNA chemical synthesis.
Key players in miRNA chemical synthesis – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Alnylam Pharmaceuticals is one of the leading patent filers for miRNAs. Alnylam discovers, develops and commercialises drugs based on RNAi interference. The company develops a broad pipeline of investigational drugs in the areas of metabolic disorders, genito urinary system and sex hormones, haematological disorders, cardiovascular, musculoskeletal disorders, and others. The company’s RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1 (PH1).
In terms of application diversity, Ansun Biopharma is the top company, followed by AusHealth and Stemlab. By means of geographic reach, European Molecular Biology Laboratory holds the top position. AusHealth and Yuhan are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Source link
#leading #innovators #miRNA #chemical #synthesis #pharmaceutical #industry
